• Study evaluates infection risk in new users of biologics for psoriasis

    1 month ago - By Healio

    Patients with psoriasis initially treated with infliximab or adalimumab had an increased risk for serious infection; however, those treated with IL-12/23, IL-17 or IL-23 inhibitors had a lower infection risk, according to a study.
    “Systemic nonbiologic therapies, targeted therapies or biologics are commonly used to manage moderate to severe psoriasis, with higher efficacy for biologic than nonbiologic agents,” Laetitia Penso, MSc, and colleagues wrote. “With the fast emergence of these new therapeutic agents, evaluating long-term comparative safety in a real-world setting is
    Read more ...